2.1701.40% ( +0.030 )
Closed: Oct 28, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -2.62, within the reasonable range, cheaper than 51.34% of the time in the past 5 years, and the industry ranks 309/606, the industry Median -2.02.
-2.62xP/E
$2.17Stock price
$-0.83Earnings per share
-2.62xP/E
Stock price$2.17Earnings per share$-0.83
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.56x
- Typical range
- -6.29x–-1.23x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
021426384
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -60.93x | 151.28% | $197.40B |
MRNAUSModerna | -27.13x | 17.00% | $85.50B |
CSLLYUSCSL Limited | -25.82x | -- | $66.59B |
NTRAUSNatera | -318.06x | 5.57% | $61.18B |
RVMDUSRevolution Medicines | -22.88x | 61.94% | $40.45B |
ROIVUSRoivant Sciences | -100.68x | 146.69% | $26.81B |
BNTXUSBioNTech SE | -11.31x | 18.75% | $22.10B |
INSMUSInsmed | -24.20x | 75.01% | $21.18B |
BBIOUSBridgebio Pharma | -20.01x | 27.56% | $13.84B |
SMMTUSSummit Therapeutics | -14.70x | 20.08% | $12.58B |
TWSTUSTwist Bioscience | -83.52x | 28.63% | $11.42B |
KYMRUSKymera Therapeutics | -34.00x | 5.24% | $10.19B |
MDGLUSMadrigal Pharma | -30.63x | 51.30% | $9.96B |
PCVXUSVaxcyte | -9.09x | 47.91% | $9.67B |
IBRXUSImmunityBio | -9.41x | 151.32% | $9.34B |
SYREUSSpyre Therapeutics | -58.55x | 45.60% | $8.80B |
CYTKUSCytokinetics | -9.53x | 6.85% | $8.52B |
ARWRUSArrowHead Pharma | -26.58x | 35,923.70% | $8.50B |
PRAXUSPraxis Precision Medicines | -23.50x | 3.71% | $7.97B |
ABVXUSAbivax SA | -16.84x | 22.99% | $7.83B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
